VRC01 Antibody Blocked 66.3% of Sensitive HIV Strains—Then Resistance Emerged

The broadly neutralizing antibody VRC01 delivered 66.3% cumulative prevention efficacy against highly sensitive HIV-1 strains—but after infusions stopped, diagnoses of antibody-resistant virus climbed above placebo levels. That's the core result of a new analysis of two landmark prevention trials, published in Science Translational Medicine under the title "Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections."

The numbers come from HVTN 704 and HPTN 085, two parallel antibody-mediated prevention (AMP) trials run in the Americas and sub-Saharan Africa. They were the first trials ever to test whether intravenous infusion of a broadly neutralizing antibody could stop HIV-1 acquisition in people who don't have the virus.

Why the AMP trials matter

VRC01 targets the CD4-binding site on the HIV-1 envelope glycoprotein. By locking onto that region, the antibody can neutralize susceptible viral strains before they infect host cells at common exposure sites. It's a prophylactic strategy aimed at HIV-negative people at risk of acquisition: those with partners living with HIV, people with ongoing sexual exposure risk, people who can't or won't take conventional PrEP, and high-incidence populations—communities in parts of sub-Saharan Africa with substantial transmission, for example.

Participants in both trials received VRC01 infusions for 80 weeks, with the final dose at week 72. The new analysis didn't stop there. The researchers tracked HIV-1 acquisition all the way through the week 104 final study visit, focusing on what happened after treatment ended.

What did the data show?

Two findings, moving in opposite directions.

Against viruses classed as highly sensitive to the antibody, VRC01 held strong. "VRC01 prophylaxis maintained cumulative prevention efficacy of 66.3%, suggesting that the antibody successfully blocked or cleared these infections," the authors write.

But as antibody concentrations fell after the last infusion, suppressed viruses re-emerged as detectable infections. Many of those viruses had evolved greater resistance under selective pressure. "In the post–week 80 period (after the final dose at week 72), HIV diagnosis and resistance to VRC01 were more frequent and greater in the VRC01 groups versus placebo," the paper states.

That's the sting in the data. The antibody worked while it was present at sufficient levels, yet the waning phase left a window where resistant strains broke through at rates exceeding placebo.

What does this change for bnAb development?

The authors draw a direct design conclusion: single antibodies are not enough. "Whereas single antibodies can block sensitive strains, multiple antibodies are likely required to prevent both viral escape and breakthrough infections," they write.

For R&D managers running HIV-1 broadly neutralizing antibody programs, the analysis also carries a methodological warning. Future bnAb trials, the authors argue, need to test for the virus well after infusions end—not just during the dosing period. Standard endpoints that stop at the last infusion could miss the delayed breakthrough infections documented here between weeks 80 and 104.

VRC01 had already progressed to large-scale clinical trials before this analysis. The open question, which this work sharpens, is whether any single-agent bnAb can deliver meaningful real-world protection against the evolving diversity of HIV strains—especially once antibody levels decline.

The next generation of trials will likely test combinations: multiple antibodies hitting different Env targets simultaneously, designed to close the escape routes that VRC01 alone left open.